FDA Finally Admits GLP-1 Drugs Can Cause Blindness: I’ve Been Warning About These Weight-Loss Shortcuts for Years

FDA's acknowledgment that GLP‑1 drugs such as Ozempic, Wegovy, Mounjaro, Zepbound and Soliqua can cause blindness marks a watershed moment for health‑focused websites, especially those publishing drug reviews, weight‑loss advice, or patient testimonies. The agency’s formal warning is likely to trigger a surge in AI‑generated content that attempts to reinterpret or downplay the risk, as automated health bots scramble to capitalize on the heightened public interest and SEO opportunities surrounding “GLP‑1 blindness” queries. For website owners, this means an immediate uptick in AI‑driven traffic that may attempt to spread misinformation or manipulate search rankings by republishing outdated claims about the safety of these injectables. Such bots can also harvest user comments and medical disclosures, creating privacy and liability concerns. Moreover, search engines may flag sites that host unverified or AI‑fabricated health claims, potentially impacting rankings and ad revenue. **Actionable tips:** 1. Update your llms.txt to explicitly disallow AI crawlers from indexing pages that discuss GLP‑1 drugs, using a rule like `User‑Agent: *Bot* Disallow: /glp-1/`. 2. Deploy a bot‑detection script that flags sudden spikes in requests from known health‑content generators (e.g., “HealthBot”, “MedCrawler”) and redirects them to a verification page. 3. Add structured data (schema.org/MedicalCondition) with authoritative sources and a “no‑AI‑summary” meta tag to signal to search engines that your content is human‑curated and should not be auto‑summarized.